WEBULL
WebtradeDownload

Biogen (BIIB) Sees Canada Back LEQEMBI As Fair Value Stays In Focus

Simply Wall St · 1d ago

Eisai and Biogen (BIIB) just cleared a key hurdle in Canada, with the national drug agency issuing a final recommendation supporting public reimbursement for Alzheimer’s therapy LEQEMBI for eligible early stage patients.

For investors, the LEQEMBI update comes at a time when Biogen’s momentum has been rebuilding, with a 1-day share price return of 2.23% and a year-to-date share price return of 21.15%, while the 1-year total shareholder return of 44.74% contrasts with declines in the 3- and 5-year total shareholder returns. This suggests that confidence has improved recently after a tougher multiyear stretch.

Scan beyond Biogen to identify other healthcare players with rebuilding momentum and solid fundamentals using our curated list of solid balance sheet and fundamentals (23 results).

Biogen’s sharp rebound and the fresh LEQEMBI catalyst put a familiar dilemma in front of you. Is this the moment to lean in, or does the recent run make patience the better value call?

Most Popular Narrative: 8.8% Undervalued

Biogen’s most followed narrative pegs fair value at $236.22 per share, which sits above the last close of $215.43 and frames the current rebound through a valuation lens.

Biogen is positioned for long-term growth through expanding global access to key therapies, leveraging increasing disease diagnoses and improved healthcare infrastructure. Streamlined operations, diverse late-stage pipeline, and digital engagement efforts are expected to strengthen earnings and reduce future revenue volatility.

Read the complete narrative. Read the complete narrative.

Want to see what underpins that higher fair value? The narrative leans on steady top line expansion, a sharp inflection in profit margins, and a richer future earnings multiple. Curious how those moving parts connect to that discount rate and still land on an undervalued signal for Biogen?

Result: Fair Value of $236.22 (UNDERVALUED)

Have a read of the narrative in full and understand what's behind the forecasts.

Still, Biogen’s story can break if key launches like LEQEMBI or ZURZUVAE stumble on uptake, or if pricing and reimbursement pressure tightens further.

Find out about the key risks to this Biogen narrative.

Another View: Multiples Paint a Tougher Picture for Biogen

The first narrative leans on a fair value of $236.22 for Biogen, but the market’s current P/E of 38.1x tells a different story. That ratio sits well above both the US Biotechs industry at 16.5x and peer average at 23.3x, and even above a fair ratio of 28.9x. This combination points to valuation risk if sentiment cools.

Seen through this lens, the stock already bakes in a lot of optimism. If earnings do not track those higher expectations, the share price could end up converging toward that lower fair ratio rather than the higher narrative value.

See what the numbers say about this price — find out in our valuation breakdown.

NasdaqGS:BIIB P/E Ratio as at Sep 2026
NasdaqGS:BIIB P/E Ratio as at Sep 2026

Next Steps

The story around Biogen is mixed enough that no single narrative feels definitive. Take a close look at the numbers, sentiment and catalysts yourself, then weigh both sides by starting with the 2 key rewards and 2 important warning signs.

Looking for more ideas beyond Biogen?

You have seen how quickly a story can change for Biogen. Now give yourself the same edge across the market by scouting fresh opportunities before they move.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.